Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 13/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14688575 | 0.81 | MAPK14 (0.40) | USP7DHODHHDAC9MAPK14NPC1 | |
| SCHEMBL18850703 | 0.81 | HDAC9 (0.46) | DHODHHDAC9MAPK14NPC1TNF | |
| SCHEMBL25929908 | 0.79 | USP7 (0.51) | USP7DHODHHDAC9MAPK14HPGDS | |
| SCHEMBL7961456 | 0.76 | USP7 (0.51) | USP7HDAC9NPC1RAB9A | |
| SCHEMBL18825197 | 0.76 | CA1 (0.50) | USP7DHODHNPC1TNFNR2F2 | |
| SCHEMBL18457022 | 0.75 | TNF (0.47) | DHODHHDAC9NPC1TNFNR2F2 | |
| SCHEMBL18850984 | 0.74 | DHODH (0.58) | DHODHNPC1TNFNR2F2RAB9A | |
| SCHEMBL18825149 | 0.74 | DHODH (0.58) | DHODHNPC1TNFNR2F2RAB9A | |
| SCHEMBL19594173 | 0.73 | PDK2 (0.47) | HDAC9HPGDS | |
| SCHEMBL15838966 | 0.73 | CYP11B1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974424-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | Genase Therapeutics B.V. (NL) | 2022-03-30 | — | — | EP | disclosed |
| EP-3371172-B1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B V (NL) | 2021-10-20 | — | — | EP | disclosed |